CLO22-074: Patient-Reported Outcomes (PROs) in Patients (pts) With Advanced Non-Small Cell Lung Cancer (aNSCLC) With Programmed Cell Death-Ligand 1 (PD-L1) ≥50% Receiving Cemiplimab (CEMI) Monotherapy Versus Platinum-Doublet Chemotherapy (CHEMO): A Focus on the EMPOWER-Lung 1 Brain Metastases Subpopulation

Mustafa Özgüroğlu,Igor Bondarenko,Ruben Gw Quek,Ahmet Sezer,Petra Rietschel,Saadettin Kilickap,Mahmut Gümüş,Xuanyao He,Giuseppe Gullo,Jennifer Mcginniss,Miranda Gogishvili

doi:10.6004/jnccn.2021.7246

CLO22-074: Patient-Reported Outcomes (PROs) in Patients (pts) With Advanced Non-Small Cell Lung Cancer (aNSCLC) With Programmed Cell Death-Ligand 1 (PD-L1) ≥50% Receiving Cemiplimab (CEMI) Monotherapy Versus Platinum-Doublet Chemotherapy (CHEMO): A Focus on the EMPOWER-Lung 1 Brain Metastases Subpopulation

Mustafa Özgüroğlu, Igor Bondarenko + Show 9 more

https://doi.org/10.6004/jnccn.2021.7246

Copy DOI

Journal: Journal of the National Comprehensive Cancer Network

Publication Date: Mar 31, 2022

Affiliation: Istanbul University-Cerrahpaşa, Dnipropetrovsk State Medical Academy, Regeneron (United States), Başkent University, Istinye University, Istanbul Medeniyet University

#Programmed Cell Death-ligand 1 #Advanced Non-Small Cell Lung Cancer + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

"CLO22-074: Patient-Reported Outcomes (PROs) in Patients (pts) With Advanced Non-Small Cell Lung Cancer (aNSCLC) With Programmed Cell Death-Ligand 1 (PD-L1) ≥50% Receiving Cemiplimab (CEMI) Monotherapy Versus Platinum-Doublet Chemotherapy (CHEMO): A Focus on the EMPOWER-Lung 1 Brain Metastases Subpopulation" published on 31 Mar 2022 by National Comprehensive Cancer Network.

Full Text